Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 147.57B | 142.99B | 143.04B | 115.58B | 103.25B |
Gross Profit | 30.68B | 28.01B | 30.14B | 26.15B | 25.18B |
EBITDA | 14.35B | 14.87B | 15.55B | 12.97B | 15.38B |
Net Income | 5.96B | 6.17B | 8.59B | 5.89B | 7.12B |
Balance Sheet | |||||
Total Assets | 141.53B | 136.31B | 126.65B | 121.27B | 107.83B |
Cash, Cash Equivalents and Short-Term Investments | 16.86B | 21.66B | 23.55B | 29.25B | 25.66B |
Total Debt | 18.86B | 11.57B | 12.62B | 14.55B | 14.09B |
Total Liabilities | 47.22B | 41.25B | 39.99B | 39.37B | 32.34B |
Stockholders Equity | 94.31B | 95.05B | 86.66B | 78.73B | 72.79B |
Cash Flow | |||||
Free Cash Flow | -5.98B | 2.04B | -128.00M | 5.39B | 13.18B |
Operating Cash Flow | 13.68B | 12.01B | 6.70B | 9.02B | 16.25B |
Investing Cash Flow | -20.91B | -10.37B | -5.94B | -4.32B | -2.23B |
Financing Cash Flow | 3.19B | -5.77B | -8.30B | -2.99B | -3.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | ¥62.63B | 9.90 | 4.41% | 3.21% | -2.40% | ||
44 Neutral | C$979.11M | -6.82 | -13.73% | 1.75% | 17.37% | -32.84% | |
― | €359.52M | 12.45 | 9.65% | 2.58% | ― | ― | |
79 Outperform | ¥60.05B | 5.57 | 3.70% | 4.12% | 192.18% | ||
77 Outperform | ¥63.64B | 15.31 | 2.74% | 6.36% | 17.44% | ||
74 Outperform | ¥110.49B | 20.32 | 1.03% | 96.61% | 133.90% | ||
74 Outperform | ¥87.66B | 9.90 | 3.83% | 4.87% | 5.07% |
Sumitomo Seika Chemicals Co., Ltd. completed the payment procedures for issuing new shares as restricted stock compensation, following a resolution made in June 2025. This issuance involves 4,576 shares at an issuance price of 4,295 yen per share, totaling 19,653,920 yen, and is aimed at compensating certain board members and executive officers, potentially impacting the company’s governance and stakeholder alignment.
Sumitomo Seika Chemicals Co., Ltd. has announced the issuance of new shares as part of a Restricted Stock Compensation System aimed at incentivizing its Board of Directors and executive officers. This initiative is designed to enhance corporate value and strengthen alignment with shareholders by issuing 4,576 shares to eligible officers, with a total issuance amount of 19,653,920 yen. The shares are subject to transfer restrictions until the officers’ resignation or retirement, ensuring long-term commitment to the company’s goals.
Sumitomo Seika Chemicals Co., Ltd. is considering reducing its investment unit to less than JPY 500,000 to enhance stock liquidity and attract a broader investor base. The company plans to evaluate this move by considering market trends, stock prices, shareholder numbers, and potential impacts on corporate value.
Sumitomo Seika Chemicals Co., Ltd. has announced details regarding its relationship with its controlling shareholder, Sumitomo Chemical Co., Ltd. Despite being part of the Sumitomo corporate group, Sumitomo Seika maintains operational independence, with minimal dependency on transactions with its parent company. This independence is reflected in the lack of significant financial or operational constraints, allowing the company to pursue its business activities without undue influence from its controlling shareholder.
Sumitomo Seika Chemicals Co., Ltd. announced a change in its leadership, appointing Oda Yoshiaki as the new Representative Director and President, effective June 23, 2025. This strategic move aims to reinforce the company’s management and improve corporate value. Additionally, Machida Kenichiro will assume the role of Representative Director and Managing Executive Officer, reflecting the company’s focus on strengthening business management.
Sumitomo Seika Chemicals reported a 3.2% increase in net sales for the fiscal year ending March 31, 2025, with operating profit rising by 12.4%. Despite the growth in sales and operating profit, the profit attributable to owners of the parent decreased by 3.3%. The company forecasts a slight decline in net sales and operating profit for the next fiscal year, but anticipates a 12.4% increase in profit attributable to owners of the parent.
Sumitomo Seika Chemicals Co., Ltd. has announced the recognition of extraordinary losses for the fiscal year ended March 31, 2025, due to mischarging by a subsidiary and impairment losses in its Functional Materials segment. Consequently, the company has revised its full-year consolidated financial forecasts, anticipating a decrease in net sales, operating profit, ordinary profit, and profit attributable to owners of the parent, primarily due to a stronger yen and the recorded extraordinary losses.
Sumitomo Seika Chemicals Co., Ltd. announced an extraordinary loss due to a subsidiary’s mischarging of a customer for a product, resulting in a repayment of 1,355 million yen. This financial adjustment has led to a revision of the company’s full-year consolidated financial forecasts, and disciplinary actions have been taken against board members to address management responsibility.